Silymarin and epithelial cancer chemoprevention: how close we are to bedside?

Area of Science:

• Oncology
• Natural Product Chemistry
• Pharmacology

Background:

• Conventional cancer therapies often exhibit high toxicity and limited efficacy.
• There is a growing need for safer, more acceptable cancer prevention and treatment agents.
• Silymarin, derived from milk thistle, has a long history of use in liver health and demonstrates potential anticancer properties.

Purpose of the Study:

• To review the chemopreventive and therapeutic potential of silymarin and its active constituent, silibinin, in cancer.
• To discuss the role of silymarin as an adjunct therapy, potentiating chemotherapy and overcoming drug resistance.
• To highlight the organ-protective and immunostimulatory effects of silymarin in cancer treatment.

Main Methods:

• Review of in vitro and in vivo studies on silymarin's anticancer effects.
• Analysis of existing clinical trial data on silymarin in cancer patients.
• Evaluation of silymarin's mechanisms, including inhibition of multidrug resistance proteins.

Main Results:

• Silymarin demonstrates significant chemopreventive efficacy in various epithelial cancer models.
• Silymarin potentiates the efficacy of conventional chemotherapeutic drugs.
• Silymarin exhibits organ-protective effects, particularly for the liver, and possesses immunostimulatory properties.

Conclusions:

• Silymarin and silibinin show considerable promise as less toxic alternatives or adjuncts in cancer therapy.
• Further controlled clinical trials are warranted to establish the efficacy of silymarin in human cancer patients.
• The established safety profile and bioavailability of silymarin support its investigation in oncology.